Drug Trial Radar · NCT01110330
An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot
Last checked: Nov 19, 2026Latest source record: Apr 29, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
583
Actual
Start
Jul 2007
Primary completion
Oct 2008
Study completion Oct 2008
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 26, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if a new formulation of ketoconazole 2% cream is as effective as a current formulation of ketoconazole 2% cream (Nizoral) compared with placebo in treating patients with Tinea pedis, a skin infection commonly known as "athlete's foot" that is caused by a kind of mold called a fungus.
Conditions
- Tinea Pedis
Interventions
Placebo creamDrug
A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
Ketoconazole 2% cream (formulation F012) (Nizoral)Drug
A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
Ketoconazole 2% cream (formulation F126)Drug
A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Patients in the Positive Baseline Culture Set (PBCS) With Mycological Cure (MC) at Week 6Time frame: Week 6
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Bydgoszcz, Poland
Site not named
Lodz, Poland
Site not named
Lublin, Poland
Site not named
Torun, Poland
Site not named
Cardiff, United Kingdom
Site not named
Chorley, United Kingdom
Site not named
Glasgow, United Kingdom
Site not named
Liverpool, United Kingdom
Site not named
Manchester, United Kingdom
Site not named
Reading, United Kingdom
Site not named
Sunbury-on-Thames, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.